Biography
- Division:
- Division of Basic and Integrative Biological Sciences – DTCS
- Review Branch:
- Cancer Diagnosis, Prevention & Therapeutics – CDPT
- Study Section:
- Cancer Biotherapeutics Development (CBD) SBIR/STTR SEP – CDPT12
Dr. Elisaveta Voynova received her Ph.D. in immunology from the Bulgarian Academy of Science, where she developed chimeric antibodies as novel immunotherapy for autoimmune disease. She then completed her postdoctoral training at the Autoimmunity and Functional Genomics Section of the National Institute of Allergy and Infectious Diseases (NIAID). Whilst at NIAID, she discovered a new immune cell type, an atypical NK cell, that contributes to the initiation and aggravation of autoimmunity and inflammation. After NIAID, Dr. Voynova joined a preclinical drug development group (R&D) at AstraZeneca Corporation. In 2020, Dr. Voynova joined the National Cancer Institute’s (NCI) T-cell Engineering Facility, where she developed a CAR-NK cell platform for preclinical treatment of T-cell malignancies. Dr. Voynova later managed the immunophenotyping unit of the NCI’s Clinical Research Correlatives Core, assisting the Center for Cancer Research clinical investigators with her expertise in translational research. Her scientific focus includes cancer, autoimmunity, and inflammation.
